Sanofi ends 2 phase 1 cancer assets weeks after axing Sangamo dealnews2022-02-04T16:31:29+00:00February 4th, 2022|FierceBiotech|
Resignation galore: Exicure CEO resigns, CTO departs, 3 board members exit after December woesnews2022-02-04T14:59:11+00:00February 4th, 2022|FierceBiotech|
UCB races to regulators after $2.5B rare disease bet delivers data for attack on AstraZeneca and argenxnews2022-02-04T12:58:05+00:00February 4th, 2022|FierceBiotech|
Remote possibilities: United BioSource teams with Seqster to boost decentralized study offeringnews2022-02-04T12:56:29+00:00February 4th, 2022|FierceBiotech|
Pfizer’s $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to increase antibodiesnews2022-02-04T11:54:32+00:00February 4th, 2022|FierceBiotech|
Unity once again lays off large number of staff, narrows focus to ophthalmology assetsnews2022-02-03T21:32:16+00:00February 3rd, 2022|FierceBiotech|
Arrowhead ‘changing horses’ for ENaC pulmonary program as phase 1/2 asset shelvednews2022-02-03T17:01:59+00:00February 3rd, 2022|FierceBiotech|
Pfizer accuses former employees of ‘treachery’ in stealing trade secrets to form Regor Therapeuticsnews2022-02-03T14:29:33+00:00February 3rd, 2022|FierceBiotech|
Roche lets go of etro, dumping phase 3 Crohn’s prospect 18 months after posting weak colitis datanews2022-02-03T12:37:01+00:00February 3rd, 2022|FierceBiotech|
AstraZeneca punts midphase cardiovascular prospect to startupnews2022-02-03T10:32:00+00:00February 3rd, 2022|FierceBiotech|
